Starpharma Holdings Ltd has released a press release.
Positive DEP docetaxel Phase 2 results
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- AGM Chairman's address and CEO presentation
- Starpharma announces new CEO, Ms Cheryl Maley
- Starpharma receives $7.2 million R&D Tax Incentive refund
- Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer
- DEP irinotecan clinical data presented at AACR meeting
Later from Starpharma
- VivaGel BV sales and distribution agreement MENA region
- Viraleze shows antiviral efficacy in COVID-19 patients
- VivaGel BV US FDA Appeal Outcome
- S&P DJI Announces March 2024 Quarterly Rebalance
- Starpharma and Medicxi Partnership Petalion Therapeutics
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma